← All trials
NCT05680233
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 23, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Apr 30, 2024
- First posted
- Jan 11, 2023
- Last posted
- Sep 8, 2023
- Enrollment
- 23
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oasis Pharmaceuticals, LLCLead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Mayo ClinicCollaborator
- Oasis Pharmaceuticals, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.